4370-90-5

Usage

Uses

Used in Pharmaceutical Industry:
PTH-METHIONINE is used as a therapeutic agent for the treatment of hypoparathyroidism, a condition characterized by low levels of PTH. It is administered through injection to effectively regulate calcium and phosphate metabolism, providing a valuable treatment option for managing conditions related to calcium regulation.

InChI:InChI=1/C12H14N2OS2/c1-17-8-7-10-11(15)14(12(16)13-10)9-5-3-2-4-6-9/h2-6,10H,7-8H2,1H3,(H,13,16)

Upstream product

• 103-72-0 phenyl isothiocyanate 
• 59-51-8 DL-methionine 

Downstream Products

• 1062634-87-0 [CuCl(5-[2-(methylthio)ethyl]-3-phenyl-2-thioxoimidazolidin-4-one(-1H))]2 

Relevant academic research and scientific papers

Enantioselective Synthesis of 5,5-Disubstituted Hydantoins by Br?nsted Base/H-Bond Catalyst Assisted Michael Reactions of a Design Template

A new method for the enantioselective synthesis of 5,5-disubstituted (quaternary) hydantoins was developed on the basis of an organocatalytic Michael reaction approach involving the use of 2-benzylthio-3,5-dihydroimidazol-4-ones as key hydantoin surrogates. The method is general with respect to the substitution pattern at the hydantoin N1 (alkyl, aryl, acyl), N3 (aryl), and C5 (linear/branched alkyl, aryl) positions and affords essentially single diastereomeric products with enantioselectivities higher than 95 % ee in most cases. Among the bifunctional Br?nsted base/H-bond catalysts examined, a known squaramide–tertiary amine catalyst and a newly prepared squaramide–tertiary amine catalyst provide the highest selectivity so far with either nitroolefins or vinyl ketones as the acceptor components. Kinetic measurements support a first-order rate dependence on both reaction partners, the donor template and the Michael acceptor, whereas competitive 1H NMR spectroscopy experiments reveal the high ability of the template for catalyst binding.